===
EQS-News: Eckert & Ziegler SE / Key word(s): Alliance/Miscellaneous
Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility
2024-06-19 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.
June 19, 2024 - Berlin, Germany and Rez, Czech Republic - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), in
collaboration with the Nuclear Physics Institute of the Czech Academy of Sciences (Ústav jaderné fyziky, "UJF"),
announces the grand opening of a pioneering Actinium-225 (Ac-225) production facility. This milestone, celebrated
yesterday with an official ceremony featuring Czech Prime Minister Petr Fiala, marks the culmination of a longstanding
partnership between Eckert & Ziegler and UJF. The facility is now close to operational readiness, and after additional
testing, commercial production is slated to commence at the beginning of Q3/2024.
Currently, Ac-225-based radiopharmaceuticals are under clinical investigation for various cancers, including prostate
tumors, colorectal cancer, and leukemia. A substantial increase in the demand for Ac-225 is projected over the next
decade, driven by its expanding clinical applications and the promising results seen in ongoing trials. Despite its
therapeutic promise, sufficient quantities of Ac-225 remain scarce.
"Eckert & Ziegler, in conjunction with UJF, has explored one of the most promising cyclotron-based production pathways
for Ac-225," said Dr. Lutz Helmke, Managing Director of Eckert & Ziegler Radiopharma GmbH. "Our collaboration signifies
a major leap forward in isotope production, addressing the critical shortage of this isotope poised to revolutionize
modern oncology."
The newly inaugurated laboratory will leverage cutting-edge technologies, including a customized production line
provided by Isotope Technologies Dresden GmbH, which represents the Plant Engineering business of Eckert & Ziegler.
Radium-226, necessary for irradiation processes, will also be supplied by Eckert & Ziegler.
"Today's opening marks a significant achievement in our collaboration with Eckert & Ziegler," commented Prof. Ondrej
Lebeda, Head of Department of Radiopharmaceuticals at UJF. "This new facility is a testament to our joint dedication to
innovation in the therapeutic landscape for many cancer patients."
Actinium-225 has emerged as a highly promising agent in the targeted therapy of small tumors and metastases. Its
high-energy cascade of alpha particles with short penetration depths allows for precise targeting of tumor cells,
including difficult-to-reach micro metastases, while minimizing impact on surrounding healthy tissue.
About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear
medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical
industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN
DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
About UJF
The Nuclear Physics Institute of the Czech Academy of Sciences is a public research institution that conducts research
in a broad field of nuclear physics, both experimental and theoretical. Its Department of radiopharmaceuticals focuses
on the investigation and production of novel medical radionuclides as well as radionuclides important for physical
research.
Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Jan Schöpflin, Marketing / Karolin Riehle, Investor Relations
jan.schoepflin@ezag.de / karolin.riehle@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com
2024-06-19 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Eckert & Ziegler SE 

Robert-Rössle-Str.10
13125 Berlin
Germany

Phone:        +49 30 941084-138 
Fax:          +49 30 941084-0 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX, TecDax, 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 

Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1928009

End of News EQS News Service
===
1928009 2024-06-19 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1928009&application_name=news

END) Dow Jones Newswires

June 19, 2024 03:00 ET (07:00 GMT)